Julie C. DiCarlo

An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: A three‐month randomized, placebo‐controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents

Mark C. Genovese, Arthur Kavanaugh, Michael E. Weinblatt et al. · Arthritis & Rheumatism · 2010 · 209 citations

Medicine, Pharmacology, Pharmacotherapy +17

Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: the ASSET randomised controlled trial

Philip G. Conaghan, Patrick Durez, Rieke Alten et al. · Annals of the Rheumatic Diseases · 2012 · 63 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +16

Evaluating patient-specific neoadjuvant regimens for breast cancer via a mathematical model constrained by quantitative magnetic resonance imaging data

Angela M. Jarrett, David A. Hormuth, Chengyue Wu et al. · Neoplasia · 2020 · 63 citations · Full text

Medicine, Oncology, Biomedical Imaging +16

MRI assessment of suppression of structural damage in patients with rheumatoid arthritis receiving rituximab: results from the randomised, placebo-controlled, double-blind RA-SCORE study

Charles Peterfy, Paul Emery, Paul P. Tak et al. · Annals of the Rheumatic Diseases · 2014 · 59 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +17

The effects of tocilizumab on osteitis, synovitis and erosion progression in rheumatoid arthritis: results from the ACT-RAY MRI substudy

Philip G. Conaghan, Charles Peterfy, Ewa Olech et al. · Annals of the Rheumatic Diseases · 2014 · 47 citations · Full text

Medicine, Pharmacotherapy, Radiology +16